NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Nov 2005
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
EXJADE (deferasirox) by Novartis is iron chelating activity [moa]. Approved for iron chelator [epc]. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXJADE (deferasirox) is an oral iron chelator approved in 2005 for managing iron overload in patients with chronic transfusion-dependent anemias and hereditary iron disorders. It binds excess iron and facilitates urinary and fecal excretion, reducing iron-induced organ damage. The drug is indicated across 11 conditions including beta-thalassemia, sickle cell disease, myelodysplastic syndromes, and hereditary hemochromatosis.
$3MPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D spending ($3M, 232 claims in 2023), signaling a mature, stable but smaller commercial footprint requiring defensive positioning strategies.
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
Started Jan 2024
400 enrolled
Chronic Iron Overload
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Started Oct 2019
11 enrolled
Myelodysplastic Syndromes
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Started Feb 2018
39 enrolled
Myelodysplasia
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Started Jan 2018
44 enrolled
Iron Overload
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Started Jan 2018
45 enrolled
Hereditary Hemochromatosis
Worked on EXJADE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.